LEADER 02017nam  2200361   450 
001 9910688340203321
005 20230702065843.0
035   $a(CKB)3800000000216533
035   $a(NjHacI)993800000000216533
035   $a(EXLCZ)993800000000216533
100   $a20230702d2017      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aNovel Pharmacological Inhibitors for Bacterial Protein Toxins /$fedited by Holger Barth
210  1$aBasel :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2017.
215   $a1 online resource (v, 103 pages)
311   $a3-03842-431-5 
330   $aMany medically relevant bacteria cause severe human and animal diseases because they produce and release protein toxins that target mammalian cells. Because the toxin-induced cell damage is the reason for the clinical symptoms, the targeted pharmacological inhibition of the cytotoxic mode of action of bacterial toxins should prevent or cure the respective toxin-associated disease. Toxin inhibitors might be beneficial when the toxin acts in the absence of the producing bacteria (e.g., food poisoning), but also in combination with antibiotics in infectious diseases when the toxin-producing bacteria are present. The focus of this Special Issue of Toxins is on the development and characterization of novel inhibitors against bacterial toxins, e.g., toxin neutralizing antibodies, peptides or small compounds, as well as toxin pore blockers, which interfere with bacterial toxins and thereby protect cells from intoxication.
606   $aBacterial proteins
606   $aBacterial toxins
615  0$aBacterial proteins.
615  0$aBacterial toxins.
676   $a572.69
702   $aBarth$b Holger
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688340203321
996   $aNovel Pharmacological Inhibitors for Bacterial Protein Toxins$93114709
997   $aUNINA